RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Longitudinal Modeling of Informatively Censored Patient-Reported Outcomes Data in Oncology: Application to a Phase Iii Clinical Trial of Non-Small Cell Lung Cancer
Application to a Phase Iii Clinical Trial of Non-Small Cell Lung Cancer [MEETING ABSTRACT PCN139]
Houghton, K., Boye, M., Bowman, L., Brown, J., & Stull, D. (2016). Longitudinal Modeling of Informatively Censored Patient-Reported Outcomes Data in Oncology: Application to a Phase Iii Clinical Trial of Non-Small Cell Lung Cancer: Application to a Phase Iii Clinical Trial of Non-Small Cell Lung Cancer [MEETING ABSTRACT PCN139]. Value in Health, 19(3), A158-AA159. https://doi.org/10.1016/j.jval.2016.03.1473
This is the first known example that directly demonstrates how PRO response is associated with OS through use of joint latent-variable PMM. Moreover, results show that use of PMM with OS analyses provides a greater understanding of treatment effect.